Changes in Hong Kong stocks | Peger Biopharmaceutical-B (02565) rose more than 5% and joined hands with the three parties to accelerate the opening up of the Paidacang commercial link product market

The Zhitong Finance App learned that Peger Biopharmaceutical-B (02565) rose by more than 5%. As of press release, it had risen 5.41% to HK$7.01 to HK$132 million.

According to news, on July 17, Peger Biopharmaceutical-B, Shanghai Tengrui Pharmaceutical Co., Ltd. and Alibaba Health (00241) formally signed a strategic cooperation agreement in Hangzhou. ^{The three parties will make full use of their respective advantages in innovative drug research and development, professional commercialization and digital medical services to jointly promote online accessibility and patient services for the Class 1 innovative drug Pidacang® (generic name: vipernatide injection) originally developed in China.} According to the cooperation arrangement, Ali Health will rely on full-link service capabilities such as online consultation, prescription circulation, pharmacist review, professional delivery and medication guidance to expand the online diagnosis, treatment and patient service scenarios of Paidacan®.

In the next phase, the market's focus on Pidacang ^{® will shift from “whether the product can be approved” to the speed of dosage brought} about by hospital coverage, doctors' prescriptions, continuous patient medication use, and online and offline collaboration. ^{For Peger Biotech, the strategic cooperation with Tengrui Pharmaceuticals and Alibaba Health has not only further improved the commercialization layout of Pidacang®, but also sent a clearer signal: with product differentiation, a national promotion network, and the gradual convergence of digital patient portals, Pidacang® is accelerating from the commercial preparation stage to the real market verification stage, and the future volume is ready to go.}